In addition, the combination of eribulin and pembrolizumab showed good antitumor effect for both PD-L1 positive and negative tumors in mTNBC, but the ORR of PD-L1 positive tumor patients was higher than that of PD-L1 negative [41]. This evidence concerns the gene CD274 and neoplasm.